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Abstract
Background: Activating transcription factor 3 (ATF3) is a negative regulator of proinflammatory cytokine expression in
macrophages, and ATF3 deficient mice are more susceptible to endotoxic shock. This study addresses the role of ATF3 in
the Kdo2-Lipid A-induced Toll-like receptor 4 (TLR4) signaling pathway in mouse embryonic fibroblasts (MEF). Kdo2-Lipid A
upregulates ATF3 expression in wild type MEF cells and induces both nuclear factor kappa B (NF-kB) and c-Jun N-terminal
kinase (JNK) activation via the TLR4 signaling pathway, while neither of these pathways is activated in ATF3-/- MEF cells.
Interestingly, in contrast to Kdo2-Lipid A, the activation of both NF-kB and JNK by TNF-a was normal in ATF3-/- MEF cells.
Methodology/Principal Findings: We found that several genes were dramatically upregulated in ATF3+/+ MEF cells in
response to Kdo2-Lipid A treatment, while little difference was observed in the ATF3-/- MEF cells. However, we also found
that the signal intensities of IkBf in ATF3-/- MEF cells were substantially higher than those in wild type MEF cells upon
microarray analyses, and upregulated IkBf expression was detected in the cytosol fraction.
Conclusions/Significance: Our findings indicate that ATF3 deficiency affects Kdo2-Lipid A-induced TLR4 signaling pathways
in MEF cells, that it may upregulate IkBf expression and that the high levels of IkBf expression in ATF3-/- cells disrupts Kdo2-
Lipid A-mediated signaling pathways.
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Introduction
Toll-like receptors (TLRs) are membrane-bound pattern-
recognition receptors (PRRs) that sense a variety of microbial-
specific motifs to trigger an innate immune response [1,2]. To
date, 13 mammalian TLRs have been identified, each of which
detects specific ligands derived from invading microbes [3]. TLRs
consist of an outward leucine-rich repeat (LRR) motif, a
transmembrane domain and an inward Toll/interleukin-1 recep-
tor (TIR) domain [4,5]. TLRs are localized on the cytoplasmic or
endosomal membrane, where they recognize diverse pattern-
associated molecular patterns (PAMPs) such as bacterial lipopoly-
saccharide (LPS) or microbial nucleic acids through their LRR
motifs [6]. Once a LRR motif is engaged by PAMPs, TLRs initiate
specific signaling pathways via the recruitment of TIR domain-
containing adaptor molecules such as myeloid differentiation
primary response protein 88 (MyD88) or TIR domain-containing
adaptor inducing IFN-b (TRIF) [7,8].
TLR4 selectively recognizes LPS, a major outer membrane
component of gram-negative bacteria, in cooperation with co-
receptor MD2 [9]. LPS is composed of a lipid A portion that is
responsible for its toxic properties, as well as a core polysaccharide
and O-specific polysaccharide [10,11]. Recently, the linkage of 3-
deoxy-D-manno-octulosonic acid (Kdo), a component of the core
polysaccharide, to lipid A was shown to be sufficient to induce the
endotoxin activity of LPS [12]. Structural analyses have also
revealed that the binding of LPS to TLR4-MD2 induces
dimerization of the TLR4-MD2 complex, leading to activation
of downstream signaling pathways [13]. Upon stimulation with
LPS, TLR4 recruits MAL and TRIF through its TIR domain and
then initiates a series of signaling cascades that result in the
activation of nuclear factor kappa B (NF-kB) and mitogen-
activated protein kinases (MAPKs) [14,15].
Activating transcription factor 3 (ATF3) is a member of the ATF/
cAMP response element binding-protein (CREB) family of basic-
region leucine zipper (bZIP)type transcription factors.ATF3 binds to
a cAMP response element sequence through its basic-region and
forms homo- or heterodimers with other CREB family members
through its bZip domain [16,17]. ATF3 has been shown to repress or
activate the transcription of target genes depending on the cell
context [17,18]. In contrast to the implication of its name, ATF3 is a
homodimer that functions as a transcriptional activator [19]. ATF3 is
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including cytokines and physiological stresses [20]. In macrophages,
ATF3 has been shown to be induced by the TLR4 ligand, LPS and
bacillus Calmette Guerin (BCG), as well as by IFN a, b and c in
human PBMC [18]. Despite these observations, the role that ATF3
plays in innate immune responses has only been recently described
[21]. Activation of the TLR signaling pathways has been shown to
induce the expression of ATF3, which subsequently regulates the
transcription of NF-kB-dependent genes such as IL-6 and IL-12b
[21]. Studies involving ATF3-deficient mice have revealed that
elevated cytokines were present in ATF3-/- mice upon stimulation
with LPS, indicating that ATF3 negatively regulates the transcription
of NF-kB-dependent genes [22]. It has also been shown that ATF3 is
involved in regulation of the cell cycle and apoptosis; however, the
biological role of ATF3 is still the subject of debate [23,24].
In the present study, we investigated the function of ATF3 in
the Kdo2-Lipid A-mediated TLR4 signaling pathways in mouse
embryonic fibroblast (MEF) cells. We found that several genes
were dramatically upregulated in wild type MEF cells upon Kdo2-
Lipid A treatment and that they subsequently induced the TLR4
pathway, but that the treatment had little effect on these genes in
ATF3 knockout cells. These findings suggest that ATF3 plays a
role in TLR4-mediated gene expression. Additionally, our
microarray data revealed that the basal level of IkBf mRNA is
relatively higher in ATF3-/- MEF cells, which was confirmed by
the protein levels in these cells. Moreover, our results showed that
high levels of IkBf may inhibit Kdo2-Lipid A-mediated NF-kB
activation in ATF3-/- MEF cells. We also demonstrated that
Kdo2-Lipid A-induced activation of both NF-kB and JNK was
affected in the absence of ATF3, but that the TNF-induced
activation of NF-kB, JNK and cell death was normal. Thus, both
NF-kB and JNK activation are regulated by ATF3 via the TLR4
signaling pathway. The negative feedback role of ATF3 for
controlling cytokine toxicity provides an advantage as a model of
infection with high clinical relevance. The role of ATF3 immune
regulation and connections to infection associated diseases
warrants further study.
Results
ATF3 is indispensable for Kdo2-Lipid A-induced NF-kB
and JNK activation
To gain insight into the biological role of ATF3 in TLR4-
mediated signaling pathways, we treated MEF with Kdo2-Lipid A.
Kdo2-Lipid A treatment caused degradation of IkB, which is an
essential step in NF-kB activation that also leads to a significant
increase in the cellular level of ATF3 in wild type MEF cells
(Fig. 1A). Surprisingly, early degradation of IkBa was abrogated in
ATF3-/- MEF cells that were treated with Kdo2-Lipid A,
indicating that ATF3 is required for TLR4-dependent NF-kB
activation (Fig. 1A). Next, we examined the phosphorylation of
JNK in wild type and ATF3-/- MEF cells following Kdo2-Lipid A
treatment. LPS stimulation was shown to activate the JNK
signaling pathway in addition to NF-kB via the TLR4 signaling
pathway. Similar to NF-kB activation, the Kdo2-Lipid A-induced
phosphorylation of JNK was completely blocked in ATF3-/- MEF
cells, whereas these pathways were potently activated in ATF3+/+
MEF cells at 30 min (Fig. 1B). To confirm these findings, we
evaluated ATF3 to determine if it is critical for TLR-dependent
NF-kB activation in response to LPS, which is a potent activator of
TLR4-dependent NF-kB activation [14]. As shown in Figure 1C,
both LPS and Kdo2-Lipid A induced phosphorylation of IkBa at
15 min and degradation of IkBa at 30 min in ATF3+/+ MEF
cells, but not ATF3-/- MEF cells (see Fig. S1 for further
information). We also confirmed that ATF3-dependent JNK
activation in response to both LPS and Kdo2-Lipid A induced the
TLR4 signaling pathway. As shown in Fig. 1C, both LPS and
Kdo2-Lipid A treatment led to phosphorylation of JNK at 15–
30 min in ATF3+/+ MEF cells, but not in ATF3-/- MEF cells,
suggesting that Kdo2-Lipid A has the same effect as LPS, which is
a known TLR4 activator. To further confirm that the inhibition of
IkBa degradation in ATF3-/- MEF cells was the authentic effect
of ATF3 deficiency, we examined the effect of ATF3 reconstitu-
tion in ATF3-/- MEF cells in response to Kdo2-Lipid A treatment.
Transient transfection of ATF3 plasmid into ATF3-/- MEF cells
restored the ATF3 protein levels and reconstitution of ATF3
induced IkBa degradation by Kdo2-Lipid A (Fig. 1D). Taken
Figure 1. Loss of ATF3 caused defect of NF-kB and JNK
activation upon Kdo2-Lipid A treatment in MEF cells. A. Wild
type and ATF3-/- MEF cells (5610
6 cells) were treated with Kdo2-Lipid A
(10 mg/ml) for the indicated times. Cell extracts were analyzed by
immunoblotting with anti-IkBa, anti-ATF3 and anti-actin antibodies. B.
The same cell lysates from A were analyzed by immunoblotting with
anti-p-JNK, anti-JNK, anti-ATF3 and anti-actin antibodies. C. MEF cells
were treated with 10 mg/ml of LPS or 10 mg/ml of Kdo2-Lipid A for the
indicated times. Cell extracts were analyzed by immunoblotting. D.
Western blots of ATF3-/- MEF cells transfected with mock or ATF3
plasmid and treated with Kdo2-Lipid A (10 mg/ml) for the indicated
times. These experiments were repeated three times with similar
results.
doi:10.1371/journal.pone.0014181.g001
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of both NF-kB and JNK through TLR4 signaling pathway
requires ATF3 in MEF cells.
ATF3 is dispensable for TNF-a-induced NF-kB and JNK
activation
To rule out the possibility that deletion of ATF3 caused some
defect in the receptor signaling pathways, MEF cells were treated
with TNF-a to evaluate both NF-kB and JNK activation. TNF-a
is a potent activator of both IkBa degradation and JNK
phosphorylation to mediate inflammation and cell survival [25].
IkBa degradation and JNK phosphorylation were observed in
both ATF3+/+ and ATF3-/- MEF cells upon stimulation with
TNF-a, but only in ATF3+/+ cells following treatment with Kdo2-
Lipid A (Fig. 2A). This observation demonstrates that ATF3 is
indispensable for TLR4-mediated NF-kB and JNK activation. To
further confirm that TNF-a-induced the signaling pathway in both
ATF3+/+ and ATF3-/- MEF cells, we evaluated TNF-a-induced
cell death. Regular MEF cells undergo apoptosis in response to
treatment with the protein synthesis inhibitor, cycloheximide,
30 min before TNF-a treatment. As shown in Fig. 2B, both
ATF3+/+ and ATF3-/- MEF cells were sensitive to TNF-a-
induced apoptosis. Taken together, these results indicate that
deletion of ATF3 disrupts TLR4 mediated signaling, but not
TNFR1 in MEF cells.
ATF3 deficiency causes a defect in Kdo2-Lipid A-induced
gene transcription
A common feature of signaling through TLR4 is that the
induced expression of many of the pro-inflammatory cytokines is
dependent on both NF-kB and MAP kinase-dependent transcrip-
tion factors [26]. The results of the present study suggest that
ATF3 deficiency blocked Kdo2-Lipid A-induced TLR4 signaling
pathways in MEF cells. To further evaluate these findings, we
investigated Kdo2-Lipid A-induced gene transcription to deter-
mine if it differed between wild type and ATF3-/- MEF cells using
microarray analysis. To accomplish this, wild type and ATF3-/-
MEF cells were treated with Kdo2-Lipid A for 0.5, 1 and 2 hrs,
after which the total relative levels of TNF-a and ATF3 mRNA
were determined by RT-PCR. As shown in Fig. 3, the relative
levels of TNF-a and ATF3 increased upon Kdo2-Lipid A
treatment in wild type MEF cells, but not in ATF3-/- MEF cells.
b-actin and GAPDH were used as internal controls. These data
suggest that Kdo2-Lipid A-mediated TLR4 pathways induce the
expression of pro-inflammatory cytokines, and this was affected by
ATF3 deficiency in MEF cells.
Figure 2. ATF3 is dispensable for TNF-a-induced NF-kB and JNK activation. A. Wild type and ATF3-/- MEF cells were treated with TNF-a
(30 ng/ml) or Kdo2-Lipid A (10 mg/ml) for the indicated times, after which the cell extracts were analyzed by immunoblotting. Data are representative
of at least three independent experiments. B. TNF-a induced cell death was measured by MTT assay. Cells were pretreated for 30 min with CHX
(10 mg/ml) and then treated with TNF-a for 14 hours. The cell viability was then analyzed by MTT assay. Each data point represents the mean 6 SEM
of different experiments conducted under the same conditions. Left panel: representative images were taken by a phase-contrast microscope.
doi:10.1371/journal.pone.0014181.g002
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To evaluate the underlying mechanism of the role of ATF3, we
examined the difference in gene expression between wild type and
knockout ATF3 MEF cells using DNA microarray technology.
Differential gene expression profiles obtained after Kdo2-Lipid A
stimulation were clustered into groups of coregulated genes as
shown in Fig. 4A. The gene expression patterns in ATF3+/+ and
ATF3-/- cells that were treated with Kdo2-Lipid A were visualized
using the MeV software. Based on a threshold of $1.5-fold
increase in MEF, Kdo2-Lipid A upregulated 225 genes, 211 of
which were upregulated only in ATF3+/+ cells and five (CCL7,
Ch25h, Tnfaip3, Nfkbia, Cxcl1) of which were upregulated only in
ATF3-/- cells (Fig. 4B and Fig. S2). Of these genes, Nfkbia (IkBa
is a known transcriptional regulator. For these reason, we carefully
analyzed the IkB proteins. As shown in Fig. 5A, the signal intensity
of IkBf in ATF3-/- cells was much higher than that of ATF3+/+
cells (up to sixteen-fold when compared to the WT basal level).
However, after 1 hour of stimulation, the IkBf levels in WT cells
appeared to be the same as those in ATF3-/- cells, but the IkBf
levels of ATF3-/- MEF cells showed little change in response to
Kdo2-Lipid A treatment. IkBa was upregulated upon treatment
with Kdo2-Lipid A, which indicated that there was a feedback loop
of NF-kB activation in wild type ATF3+/+ MEF cells, but only a
slight change in ATF3-/- MEF cells (Table S1). To further
investigate this phenomenon, the total relative levels of IkBf
mRNA were determined by RT-PCR in RAW 264.7, wild type
and ATF3-/- MEF cells. As shown in Fig. 5B, ATF3-/- MEF cells
had a higher level of IkBf mRNA than macrophages or ATF3+/+
MEF cells, which is consistent with the microarray data. We also
confirmed that the level of IkBf mRNA was upregulated in
ATF3+/+ MEF cells in response to Kdo2-Lipid A treatment, but
that only slight changes were induced in ATF3-/- MEF cells
(Fig. 5C).
To determine if increased IkBf expression caused inhibition of
TLR4-dependent NF-kB activation, we used siRNA to prevent
IkBf expression in ATF3-/- MEF cells. Application of IkBf
siRNA to ATF3-/- MEFs obviously reduced IkBf mRNA levels
significantly, as indicated by a 66% decrease (Fig. 5D). As shown
in Figure 5E, the prevention of IkBf expression led to IkBa
degradation to Kdo2-Lipid A at 30 min, similar as in ATF3+/+
MEF cells. These findings indicate that upregulated IkBf
expression prevents IkBa degradation to Kdo2-Lipid A in MEF
cells. Taken together, these data suggest that a deficiency of ATF3
led to an increase of IkBf, and that this up-regulated IkBf plays an
inhibitory role in TLR4-mediated NF-kB activation.
Since our data suggested that there was a high level of IkBf
expression in ATF3-/- MEF cells, it is possible that deficiency of
ATF3 caused the upregulation of IkBf and translocation of IkBf
from the nuclear fraction into the cytosol to inhibit TLR4-
mediated NF-kB activation. To test this possibility, we examined
the localization of IkBf by fractionation experiments. As shown in
Figure 6, ATF3-/- MEF cells had a very high level of IkBf
expression in cytosol without Kdo2-Lipid A treatment, but wild
type MEF cells had a very low level of IkBf expression in cytosol.
For the loading controls, we probed the samples with anti-RIP1
antibody for the cytosolic portion and anti-lamin A antibody for
the nuclear portion. We also probed this blot with anti-ATF3
antibody to show the increase of ATF3 expression upon Kdo2-
Lipid A treatment in ATF3+/+ MEFs. We confirmed that Kdo2-
Lipid A induced NF-kB activation based on p65 translocation
from the cytosol to the nucleus only in wild type MEF cells. These
data suggest that ATF3 may function as a negative regulator of
NF-kB and can inhibit the transcription of IkBf in Kdo2-Lipid A-
mediated TLR4 signaling. Furthermore, these results indicate that
the deficiency of ATF3 up-regulates IkBf expression in the cytosol
as an inhibitor of NF-kB.
Discussion
ATF3 is maintained at very low levels in quiescent cells, but is
rapidly induced by various stresses, including UV, DNA damaging
agents and LPS, indicating that many signaling pathways may be
involved in the induction of ATF3 [27]. It was recently reported
that ATF3 is a negative regulator of TLR4, which suggests that
ATF3 regulates TLR4- stimulated inflammatory responses as part
of a negative-feedback loop [28]. TLR4 recognizes LPS, which
comprises the lipid A portion and triggers downstream signaling
pathways [29,30]. Upon stimulation with LPS, TLR4 initiates a
series of signaling cascades that result in the activation of NF-kB
and MAPKs. Chemically defined LPS, Kdo2-Lipid A, is fully
active as an endotoxin based on various biological criteria and is
highly selective for TLR4. In this study, we investigated the
function of ATF3 in the Kdo2-Lipid A-mediated TLR4 signaling
pathways in MEF cells.
As a TLR4 activator, Kdo2-Lipid A was found to have a
bioactivity similar to LPS based on NF-kB activation and
expression profiling of genes such as TNF-a, IL-1b and ATF3
in macrophages. We also showed that Kdo2-Lipid A initiates
TLR4-mediated NF-kB and JNK activation in MEF cells.
However, deficiency of ATF3 abolished TLR4-mediated NF-kB
and JNK activation, as well as the patterns observed in the gene
expression. The existing literature regarding the role of ATF3 in
TLR4-mediated signaling suggests that ATF3 acts as a negative
regulator in this pathway. Gilchrist et al. [28] demonstrated that a
substantial increase in LPS-induced IL-6 and IL-12b mRNA levels
in ATF3-/- bone-marrow derived macrophages and that LPS
induction of iNOS and TNF mRNA was similarly enhanced in
ATF3-/- mice. Conversely, ATF3 is required to activate TLR4-
mediated NF-kB and JNK in cells such as macrophages,
suggesting that ATF3 may also play a role in TLR signaling in
a cell-type specific manner.
While TNF-induced phosphorylation of JNK and degradation
of IkBa are normal in ATF3-/- MEF cells, Kdo2-Lipid A induced
IkBa degradation and JNK phosphorylation are impaired in these
cells. Therefore, deletion of ATF3 disrupts TLR4 mediated
signaling, but not TNFR1 in MEF cells. Consistent with these
findings, microarray analysis revealed that the most robust
changes in transcription were induced by Kdo2-Lipid A in wild
type MEF cells, but that few changes were induced in ATF3-/-
Figure 3. ATF3 deficiency causes a defect in Kdo2-Lipid A-
induced gene transcription. Wild type and ATF3-/- MEF cells were
treated with Kdo2-Lipid A (10 mg/ml) for the indicated times, after which
the mRNA was isolated. The total relative levels of TNF-a and ATF3
mRNA were determined by RT-PCR. DNA bands were quantified. Data
are representative of at least three independent experiments.
doi:10.1371/journal.pone.0014181.g003
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response to treatment with Kdo2-Lipid A, 211 genes were
upregulated only in ATF3+/+ cells, while 5 genes were
upregulated only in ATF3-/- cells.
One interesting gene that was significantly upregulated in
ATF3-/- cells (up to sixteen-fold when compared to the basal level
of ATF3+/+ cells) is IkBf, which is an inducible nuclear protein
that can selectively inhibit or activate certain NF-kB dimers [31].
Previous studies have suggested that IkBf functions as an
additional regulator of NF-kB activity and provides another level
of control for the activation of NF-kB-dependent target genes [32].
IkBf deficient mice show that IkBf is essential for the expression
Figure 4. DNA microarray analysis of ATF3 MEF cells upon Kdo2-Lipid A treatment. A. Wild type MEF and ATF3-/- MEF cells were
stimulated with 10 mg/ml Kdo2-Lipid A. The RNA was then isolated at the indicated times and subjected to DNA microarray analysis, after which the
genes were clustered based on their kinetic profiles using a K-means algorithm and the average log2 (treated/control) values of normalized gene
expression. B. Loss of the ATF3 gene induces distinct kinetic changes upon Kdo2-Lipid A treatment. The number of genes that showed significant
changes ($50%).
doi:10.1371/journal.pone.0014181.g004
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GM-CSF [33]. In addition to its function as a positive regulator of
NF-kB activation, it has been reported that the activity of NF-kBi s
controlled in a negative feedback loop by IkBf expression. p65
and p50 are the major subtypes of NF-kB present in MEF cells
and the mRNA expression level of p65 is five times higher than
that of p50 in both ATF3+/+ and ATF3-/- MEF cells (Table S1).
In this context, we have generated a structural model of IkBf using
molecular docking to search for potential sites of interaction
between the IkBf and p50/p65 heterodimer and the IkBf and
p50/p50 homodimer. The docking experiments revealed that the
binding of IkBf ankyrin repeats with the p50/p65 N-terminal
DNA binding domain prevents NF-kB-mediated transcriptional
activation (manuscript submitted separately). In line with its
Figure 5. ATF3 deficient MEF cells expressed a high level of IkBf. A. The gene expression patterns of the IkB family (a, b, e, f and bcl-3) in
ATF3+/+ (left) and ATF3-/- (right) MEF cells. B. Total relative levels of IkBf mRNA were determined by RT-PCR in RAW 264.7, wild type and ATF3-/- MEF
cells. C. Wild type and ATF3-/- MEF cells were treated with Kdo2-Lipid A for 1 hour, after which the mRNA was isolated. The total relative levels of IkBf
and GAPDH mRNA were determined by RT-PCR. D. Scramble (Sc; negative control) and IkBf siRNA was applied to ATF3 -/- cells for 24 h, after which
they were exposed to Kdo2-Lipid A for another 1 h. RT-PCR analysis of the IkBf mRNA was conducted. E. IkBf siRNA was applied into ATF3 -/- for 24 h
and then exposed to Kdo2-Lipid A for the indicated time points, after which the cell lysates were applied for Western blot with the indicated
antibodies. DNA bands were quantified. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0014181.g005
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levels of IkBf expression in ATF3-/- cells may disrupt Kdo2-Lipid
A-mediated signaling pathways.
It has been suggested that TLR4 leads to signal activation via
downstream signaling factors such as MyD88, IRAKs and
TRAF6, and that a TRAF6-dependent pathway engages MAPK
and IKK, resulting in activation of transcription factors that
participate in the induction of proinflammatory cytokines such as
NF-kB and AP-1 [2,34]. TRAF6 is essential for signal activation,
as TRAF6 deficiency results in defective LPS signaling [35]. Wild
type and ATF3-/- MEF cells were found to have similar levels of
TRAF6 expression under unstimulated conditions and their
expression levels were unchanged upon Kdo2-Lipid A treatment
(data not shown), which suggests that the abolished NF-kB and
JNK activation in response to Kdo2-Lipid A was not due to the
TRAF6 expression in ATF3-/- MEF cells. The differential effect
of ATF3 deletion on TLR4 signaling in MEF and macrophages
was likely due to different levels of IkBf. It has been suggested that
IkBf is induced in response to IL-1, LPS, peptidoglycan, bacterial
lipoprotein, flagellin and CpG DNA, but not TNF-a. Further-
more, this nuclear protein interacts with NF-kB via its carboxyl-
terminal ankyrin-repeats and can selectively inhibit or activate
certain NF-kB dimers. For example, IkBf provides transcription
ability to p50 homodimers when complexed with them. Con-
versely, when complexed with p65-containing dimers, IkBf can
repress transcription [31,36]. Consistent with microarray data and
RT-PCR data, we can detect high levels of IkBf expression in
ATF3-/- MEF cells. These cells showed no NF-kB activation in
response to Kdo2-Lipid A or after the prevention of IkBf
expression by knockdown led to IkBa degradation, which is
similar to the results observed in ATF3+/+ MEF cells.
Taken together, these findings suggest that a deficiency of ATF3
led to an increase of IkBf, and that this up-regulated IkBf plays an
inhibitory role in TLR4-mediated NF-kB activation. It is currently
not known if the interference from NF-kB activation in ATF3-/-
MEF cells is due to the high level of IkBf expression or cellular
localization of IkBf. Since our data shows that IkBf localized at
the cytosol fraction and that the prevention of IkBf expression by
IkBf specific-siRNA led to IkBa degradation to Kdo2-Lipid in
ATF3-/- MEF cells, IkBf may function as a negative regulator of
the NF-kB pathway in TLR4 signaling in MEF cells. Despite the
need to address the mechanisms discussed here in much greater
detail and to provide a better understanding of the physiological
functions of ATF3 in the TLR4-mediated pathway in MEF cells,
our data suggest that ATF3 plays a role in Kdo2-Lipid A-mediated
TLR4 signaling to activate NF-kB and MAP kinase, and that
ATF3 is required for TLR4-dependent gene expression through
the NF-kB pathway.
Materials and Methods
Reagents
Kdo2-Lipid A was purchased from Avantisis. Recombinant
TNF-a and recombinant IL-1b were purchased from R&D
Systems. Anti-ATF3, anti-TRAF6 and anti- IkB antibodies were
obtained from Santa Cruz Biotechnology. Anti-actin antibody was
purchased from Sigma and anti-p-IkB antibody was purchased
from Cell Signaling. Anti-p-JNK antibody was purchased from
Biosource and anti-JNK antibody was purchased from Phamin-
gen. Anti-IkBf antibody was obtained from Novus. LPS was
purchased from Sigma and CHX was purchased from Calbio-
chem.
Cell culture
Wild-type and ATF3-/- mouse embryonic fibroblast (MEF) cells
were cultured as previously described [24]. MEF cells and
RAW264.7 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. All
animal procedures were conducted in accordance with the
Sungkyunkwan University Guide for the Care and Use of
Laboratory Animals.
Western blot analysis
Protein analysis was conducted as previously described [37].
Briefly, MEF cells (5610
5 cells) were washed with PBS and
resuspended in M2 lysis buffer (20 mM Tris at pH 7, 0.5% NP-40,
250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM DTT,
0.5 mM PMSF, 20 mM b-glycerol phosphate, 1 mM sodium
vanadate, 1 mg/ml leupeptin). Samples were vortexed for lysis at
4uC for 15 min and then centrifuged at 15,0006g for 5 min at
4uC. The samples were then heated at 95uC for 5 min, after which
they were briefly cooled on ice. Following centrifugation at
15,0006g for 5 min, 50 mg of the cell lysates were fractionated by
SDS-polyacrylamide gel electrophoresis on a 12% gel. Resolved
proteins were transferred overnight to polyvinylidene difluoride
membrane in 25 mM Tris, pH 8.5, 0.2 mM glycerin, 20%
methanol at 25 V. Blots were blocked for at least 2 h with TBST
containing 10% nonfat dry milk. The proteins were visualized by
enhanced chemiluminescence (ECL) according to the manufac-
turer’s instructions (Amersham).
Nuclear extraction
Cell lysates of wild type and ATF3/- MEF cells stimulated for
the indicated times were prepared in NP40 lysis buffer
supplemented with 1 mg/ml each of leupeptin and aprotinin
and 1 mM phenyl methylsulphonyl fluoride (PMSF). After
centrifugation at 12,000 rpm for 15 min, the protein concentra-
tions of the lysates were determined using a Bio-Rad protein assay
kit. To separate the cytoplasmic and nuclear fractions, cell pellets
were processed using a NE-PER Nuclear and Cytoplasmic
Extraction kit (Thermo Fisher Scientific Inc.) according to the
manufacturer’s instructions.
RNA extraction and RT-PCR
Total RNA was isolated from MEFs according to the
manufacturer’s instructions using a RNeasy Mini Kit (Qiagen
Figure 6. Abolished TLR4 activation in ATF3-/- MEF cells due to
the up-regulation of IkBf expression. ATF3-/- MEF cells had a high
basal level of IkBf expression. Wild type and ATF3-/- MEF cells were
treated with Kdo2-Lipid A (10 mg/ml) for the indicated time and the cell
extracts were then analyzed by immunoblotting with the indicated
antibodies. These experiments were repeated three times with similar
results.
doi:10.1371/journal.pone.0014181.g006
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were determined by RT-PCR using amfiSure PCR Premix
(GenDePOT). PCR amplification was conducted using Taq
DNA polymerase in 30 amplification cycles for TNF-a,I kBf, b-
actin and GAPDH (95uC for 1 min, 60uC for 1 min, and 72uC for
1.5 min). The PCR primers were as follows: ATF3- F; 59-ATG
ATG CTT CAA CAT CCA GGC-39 and R; 59-TTA GCT CTG
CAA TGT TCC TTC-39 [38]; TNF-a-F ;5 9-AGC CCC CAG
TCT GTA TCC TT-3 and R; 59-CTC CCT TTG CAG AAC
TCA GG-39 [39]; b-actin- F; 59-TTC TTT GCA GCT CCT
TCG TTG CCG-39 and R; 59-TGG ATG GCT ACG TAC ATG
GCT GGG-39 [27]; GAPDH: F; 59-CAT GTA GGC CAT GAG
GTC CAC CAC-39 and R; 59-TGA AGC AGG CAT CTG AGG
G-39 [40]; IkBf-F ;5 9-ACA TCA CCG CAA ACG CCT ACA
CCT G-39 and R; 59-CGT GTC ACC ATC TCC GTC CCT
AGC G-39 [41]. The final PCR products were resolved in 1.5%
agarose gel and stained with ethidium bromide.
DNA microarray
Wild type MEF and ATF3-/- cells were stimulated with Kdo2 -
Lipid A (10 ug/ml) for 30 minutes, 1 hour or 2 hours. RNA
sampleswerepreparedformicroarray analysisusinga RNeasyMini
Kit (Qiagen Inc.) according to the manufacturer’s protocols.
Microarray analysis was conducted using the Illumina Bead Chip.
Briefly, 500 ng of total RNA were used to conduct in vitro
transcription amplification with the Illumina RNA amplification kit
(Ambion). The amplified RNA was then hybridized to Mouse-Ref-
v2 Expression Bead Chips containing gene-specific oligonucleotides
(,22,000 genes, Illumina, Inc., San Diego, CA) [42]. Hybridization
was detected using 1 mg/ml of Cy3-steptavidine (Amersham
Biosciences), after which the chips were scanned with an Illumina
BeadArray Reader. Image analysis was conducted using Illumina’s
Bead Studio software, and the raw data were exported into
Microsoft Access [43]. Quantile normalized data were selected
based on a p-value ,0.05 and a fold change of at least 1.5.
Microarray data analysis
The scanned data were initially analyzed using the Illumina
BeadStudio software. Intensity values derived from the hybridiza-
tion method were used, and probes that had a p-value ,0.05 were
selected for further analysis. The genes that showed higher ($50%
change) or lower expression ($50% change) in response to
treatment were categorized as upregulated or downregulated genes,
respectively. The log2 ratio value was hierarchically clustered to
visualize the patterns of gene expression change using Multiple
Experiment Viewer (www.tigr.org/software/tm4/mev.html).
IkBf knockdown
siRNAs targeting IkBf mRNA were designed and purchased
from Genolution Pharmaceuticals (Seoul, Korea). Transfection
was conducted using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. To examine the effect of siRNA,
B16F10 cells were co-transfected with 10 nM siRNA. The cells
were harvested 24 h after transfection, and the potency of siRNA
to silence IkBf expression was measured by RT-PCR using the
forward primer: 59-CAG TAT CGG GTG ACA CAG TTG G-
39, and the reverse primer: 59-GGA TAC GTC GGA TCT GTT
CTC C- 39. The siRNAs showing efficient IkBf silencing in
B16F10 cells were selected and each was transfected (30 nM) to
ATF3 -/- MEF cells. Scramble siRNA purchased from Genolution
Pharmaceuticals was applied to control cells as a negative control.
After culturing ATF3 -/- cells in medium for 24 h, siRNA
solution, which was diluted in a siRNA transfection medium, was
added to the ATF3 -/- cells. Following transfection with scrambled
or IkBf siRNA for 24 h, the medium was replaced with normal
medium, and ATF3 -/- cells were treated with Kdo2-Lipid A.
Cytotoxicity assay
TNF-induced cell death was determined using a colorimetric 3-
[4,5-dimetylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
assay. MEF cells (2610
5 cells) were cultured in 4-well plates for
14 h after treatment with TNF-a (30 ng/ml). Next, 20 ml of MTT
solution (5 mg/ml) were added and the cells were incubated at
37uC for an additional 4 h. After washing the supernatant out, the
insoluble formazan product was dissolved in DMSO. The optical
density of the 96-well culture plates was then measured at 570 nm
using an ELISA reader. The optical density of formazan formed in
untreated control cells was taken to indicate 100% viability.
Statistical analysis
Statistical analysis was conducted using the Illumina BeadStudio
software. The data represents the mean and standard errorofthe mean
(SEM) of different experiments under the same conditions. All results
shown are representative of three experiments that were conducted
independently. Treated groups and the controls were compared using
a Student’s t-test and a p,0.05 was considered significant.
Supporting Information
Figure S1 Both LPS and Kdo2-Lipid A induced NF-kB
activation in ATF3+/+ MEF cells, but not in ATF3-/- MEF
cells. Wild type and ATF3-/- MEF cells were treated with either
LPS (10 mg/ml) or Kdo2-Lipid A (10 mg/ml) for 30 min. Cell
lysates were applied for the Western blot with the indicated
antibodies to show that both TLR4 activators had the same effect
on NF-kB activation.
Found at: doi:10.1371/journal.pone.0014181.s001 (0.14MBDOC)
Figure S2 DNA microarray analysis of ATF3 MEF cells upon
Kdo2-Lipid A treatment. The dendrogram shows hierarchi-
cally clustered transcriptional changes induced by treatment with
Kdo2-Lipid A in wild type and ATF3-/- MEF cells for the
indicated times.
Found at: doi:10.1371/journal.pone.0014181.s002 (0.31MBDOC)
Table S1 Gene expression profile of the IkB and NF-kB
families. The numbers indicate the relative hybridization intensi-
ties observed upon analysis by an Illumina Bead Array.
Found at: doi:10.1371/journal.pone.0014181.s003 (0.04MBDOC)
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